Yubo International Biotech Limited
Yubo International Biotech Limited, through its subsidiaries, focuses on the research, development, and application of endometrial stem cells. The company offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting ser… Read more
Yubo International Biotech Limited (YBGJ) - Total Assets
Latest total assets as of September 2025: $953.21K USD
Based on the latest financial reports, Yubo International Biotech Limited (YBGJ) holds total assets worth $953.21K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Yubo International Biotech Limited - Total Assets Trend (2002–2024)
This chart illustrates how Yubo International Biotech Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Yubo International Biotech Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Yubo International Biotech Limited's total assets of $953.21K consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.5% |
| Accounts Receivable | $442.37K | 28.8% |
| Inventory | $36.95K | 2.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $50.52K | 3.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Yubo International Biotech Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yubo International Biotech Limited's current assets represent 44.5% of total assets in 2024, a decrease from 97.9% in 2002.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2024, down from 94.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 28.8% of total assets.
Yubo International Biotech Limited Competitors by Total Assets
Key competitors of Yubo International Biotech Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Yubo International Biotech Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Yubo International Biotech Limited generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Yubo International Biotech Limited is currently not profitable relative to its asset base.
Yubo International Biotech Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.25 | 0.16 | 1.49 |
| Quick Ratio | 0.24 | 0.16 | 1.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.91 Million | $ -3.77 Million | $ 631.54K |
Yubo International Biotech Limited - Advanced Valuation Insights
This section examines the relationship between Yubo International Biotech Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 61.23 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | $1.53 Million |
| Market Capitalization | $740.35K USD |
Valuation Analysis
Below Book Valuation: The market values Yubo International Biotech Limited's assets below their book value (0.48 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Yubo International Biotech Limited's assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Yubo International Biotech Limited (2002–2024)
The table below shows the annual total assets of Yubo International Biotech Limited from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.53 Million | -7.94% |
| 2023-12-31 | $1.67 Million | -29.01% |
| 2022-12-31 | $2.35 Million | -48.80% |
| 2021-12-31 | $4.59 Million | +87.63% |
| 2020-12-31 | $2.44 Million | +244387.60% |
| 2019-12-31 | $1.00K | -75.00% |
| 2018-12-31 | $4.00K | -20.00% |
| 2017-12-31 | $5.00K | +25.00% |
| 2016-12-31 | $4.00K | -71.43% |
| 2015-12-31 | $14.00K | +75.00% |
| 2014-12-31 | $8.00K | 0.00% |
| 2013-12-31 | $8.00K | -46.67% |
| 2012-12-31 | $15.00K | +50.00% |
| 2011-12-31 | $10.00K | 0.00% |
| 2010-12-31 | $10.00K | +11.11% |
| 2009-12-31 | $9.00K | +125.00% |
| 2008-12-31 | $4.00K | 0.00% |
| 2007-12-31 | $4.00K | -60.00% |
| 2006-12-31 | $10.00K | -82.76% |
| 2005-12-31 | $58.00K | +5.45% |
| 2004-12-31 | $55.00K | -80.50% |
| 2003-12-31 | $282.00K | -65.23% |
| 2002-12-31 | $811.00K | -- |